PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 1987 October; 46(10): 727–733.
PMCID: PMC1003378

Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications.

Abstract

Sixteen patients with classic rheumatoid arthritis (RA) complicated by severe vasculitis were studied and compared with a matched control group of 16 RA patients without vasculitis. Seven of the patients with vasculitis died within 4 to 120 months (median 32 months) after developing vasculitic symptoms. Gangrene of digits and extremities, bowel ulcers or bowel perforation, or both, and cardiac involvement were more common among the patients who died than among those with a more favourable course. The present data suggest that large vessel vasculitis in RA is associated with high frequency of arteriosclerotic vascular disease. The serum concentrations of complement components C3 and C4 were lower, and concentrations of IgM rheumatoid factor, complement activating rheumatoid factor, and C1q binding immune complexes (C1q solid and C1q fluid phase assay) were significantly higher among vasculitic patients than in the control group. Laboratory data provided little prognostic information with regard to rheumatoid vasculitis, with the exception that IgM and IgG rheumatoid factors were significantly higher among patients with fatal course of disease than in those who achieved remission.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (931K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Panush RS, Katz P, Longley S, CarterR, Love J, Stanley H. Rheumatoid vasculitis: diagnostic and therapeutic decisions. Clin Rheumatol. 1983 Dec;2(4):321–330. [PubMed]
  • Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981 Jul;60(4):288–297. [PubMed]
  • ROPES MW, BENNETT GA, COBB S, JACOX R, JESSAR RA. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed]
  • BLUMBERG BS, BUNIM JJ, CALKINS E, PIRANI CL, ZVAIFLER NJ. ARA NOMENCLATURE AND CLASSIFICATION OF ARTHRITIS AND RHEUMATISM (TENTATIVE). Arthritis Rheum. 1964 Feb;7:93–97. [PubMed]
  • BALL J. Serum factor in rheumatoid arthritis agglutinating sensitized sheep red cells. Lancet. 1950 Nov 11;2(6637):520–524. [PubMed]
  • Truedsson L, Sjöholm AG, Sturfelt G. Complement activating rheumatoid factors in rheumatoid arthritis studied by haemolysis in gel: relation to antibody class and response to treatment with podophyllotoxin derivatives. Clin Exp Rheumatol. 1985 Jan-Mar;3(1):29–37. [PubMed]
  • Anderson SG, Bentzon MW, Houba V, Krag P. International reference preparation of rheumatoid arthritis serum. Bull World Health Organ. 1970;42(2):311–318. [PubMed]
  • Sjöholm AG. Complement components in normal serum and plasma quantitated by electroimmunoassay. Scand J Immunol. 1975;4(1):25–30. [PubMed]
  • Brandslund I, Siersted HC, Svehag SE, Teisner B. Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma. J Immunol Methods. 1981;44(1):63–71. [PubMed]
  • Zubler RH, Lange G, Lambert PH, Miescher PA. Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. J Immunol. 1976 Jan;116(1):232–235. [PubMed]
  • Scullion M, Balint G, Whaley K. Evaluation of the C1q solid-phase binding assay for immune complexes. A clinical and laboratory study. J Clin Lab Immunol. 1979 Apr;2(1):15–22. [PubMed]
  • Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21–37. [PubMed]
  • Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984 Mar;76(3):377–384. [PubMed]
  • Abel T, Andrews BS, Cunningham PH, Brunner CM, Davis JS, 4th, Horwitz DA. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980 Sep;93(3):407–413. [PubMed]
  • Winkelstein A, Starz TW, Agarwal A. Efficacy of combined therapy with plasmapheresis and immunosuppressants in rheumatoid vasculitis. J Rheumatol. 1984 Apr;11(2):162–166. [PubMed]
  • SCHMID FR, COOPER NS, ZIFF M, McEWEN C. Arteritis in rheumatoid arthritis. Am J Med. 1961 Jan;30:56–83. [PubMed]
  • BYWATERS EG, SCOTT JT. THE NATURAL HISTORY OF VASCULAR LESIONS IN RHEUMATOID ARTHRITIS. J Chronic Dis. 1963 Aug;16:905–914. [PubMed]
  • Wilkinson M, Torrance WN. Clinical background of rheumatoid vascular disease. Ann Rheum Dis. 1967 Nov;26(6):475–480. [PMC free article] [PubMed]
  • Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967 Jul;43(1):8–14. [PubMed]
  • Rus HG, Niculescu F, Constantinescu E, Cristea A, Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis. 1986 Jul;61(1):35–42. [PubMed]
  • Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971 Jan;74(1):1–12. [PubMed]
  • KEMPER JW, BAGGENSTOSS AH, SLOCUMB CH. The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis. Ann Intern Med. 1957 May;46(5):831–851. [PubMed]
  • Scott DG, Bacon PA, Allen C, Elson CJ, Wallington T. IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol. 1981 Jan;43(1):54–63. [PubMed]
  • Sturfelt G, Sjöholm AG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1984;75(1):75–83. [PubMed]
  • Sjöholm AG, Berglund K, Johnson U, Laurell AB, Sturfelt G. C1 activation, with C1q in excess of functional C1 in synovial fluid from patients with rheumatoid arthritis. Int Arch Allergy Appl Immunol. 1986;79(2):113–119. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group